JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 16, Issue 3 (2024)
Iran J War Public Health 2024, 16(3): 295-300 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2024/09/9 | Accepted: 2024/10/15 | Published: 2024/11/1
Received: 2024/09/9 | Accepted: 2024/10/15 | Published: 2024/11/1
How to cite this article
Noori T, Chiad I, Taqi F, Sabah H. Knowledge of Health & Medical Technologies’ Students about Herpes Zoster Virus. Iran J War Public Health 2024; 16 (3) :295-300
URL: http://ijwph.ir/article-1-1507-en.html
URL: http://ijwph.ir/article-1-1507-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Department of Community Health, Faculty of College of Health and Medical Technologies, Middle Technical University, Baghdad, Iraq
2- Department of Community Health, Faculty of Technical Medical Institute, Northern Technical University, Mousl, Iraq
2- Department of Community Health, Faculty of Technical Medical Institute, Northern Technical University, Mousl, Iraq
Abstract (739 Views)
Aims: Herpes zoster, or shingles, is a contagious disease caused by the reactivation of a dormant virus and its subsequent transmission along the sensory nerve to the matching dermatomes. This study was carried out to determine the level of knowledge about the herpes zoster virus among health and medical technology students.
Instrument & Methods: This is an analytic cross-sectional study of senior students of the College of Health and Medical Technologies in Baghdad, examining their knowledge of the herpes zoster virus from November 2023 to February 2024. All fourth-year students (n=215) were collected as samples. The questionnaire had nine questions. Data analysis was carried out using SPSS 24 software by the Chi-square test.
Findings: Most of the studied sample (68.4%) were in the age group 20-24 years (24.6±3.4); 57.2% were female, 83.3% were single, and 84.7% lived in urban areas. Information was received from studying (45.1%), health workers (14.4%), family (12.1%), friends (11.2%), the internet (8.4%), and other sources (8.8%). Most study samples had acceptable knowledge scores; 36% were weak, and 8% had good scores. No significant associations were found between knowledge score and demographic variables.
Conclusion: The overall knowledge score regarding herpes zoster virus among students of the College of Health and Medical Technologies in all departments is acceptable.
Instrument & Methods: This is an analytic cross-sectional study of senior students of the College of Health and Medical Technologies in Baghdad, examining their knowledge of the herpes zoster virus from November 2023 to February 2024. All fourth-year students (n=215) were collected as samples. The questionnaire had nine questions. Data analysis was carried out using SPSS 24 software by the Chi-square test.
Findings: Most of the studied sample (68.4%) were in the age group 20-24 years (24.6±3.4); 57.2% were female, 83.3% were single, and 84.7% lived in urban areas. Information was received from studying (45.1%), health workers (14.4%), family (12.1%), friends (11.2%), the internet (8.4%), and other sources (8.8%). Most study samples had acceptable knowledge scores; 36% were weak, and 8% had good scores. No significant associations were found between knowledge score and demographic variables.
Conclusion: The overall knowledge score regarding herpes zoster virus among students of the College of Health and Medical Technologies in all departments is acceptable.
References
1. Blair RJ. Varicella zoster virus. Pediatr Rev. 2019;40(7):375-7. [Link] [DOI:10.1542/pir.2017-0242]
2. Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013;369(3):255-63. [Link] [DOI:10.1056/NEJMcp1302674]
3. Freer G, Pistello M. Varicella-zoster virus infection: Natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018;41(2):95-105. [Link]
4. Johnson RW, Alvarez-Pasquin MJ, Bijl M, Franco E, Gaillat J, Clara JG, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: A multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109-20. [Link] [DOI:10.1177/2051013615599151]
5. Schmader K. Herpes zoster. Clin Geriatr Med. 2016;32(3):539-53. [Link] [DOI:10.1016/j.cger.2016.02.011]
6. Babamahmoodi F, Alikhani A, Ahangarkani F, Delavarian L, Barani H, Babamahmoodi A. Clinical manifestations of herpes zoster, its comorbidities, and its complications in North of Iran from 2007 to 2013. Neurol Res Int. 2015;2015:896098. [Link] [DOI:10.1155/2015/896098]
7. Shearer K, Maskew M, Ajayi T, Berhanu R, Majuba P, Sanne I, et al. Incidence and predictors of herpes zoster among antiretroviral therapy-naive patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014;23:56-62. [Link] [DOI:10.1016/j.ijid.2013.10.016]
8. Johnson R, Rice A. Clinical practice: postherpetic neuralgia. N Engl J Med. 2014;371:1526-1533. [Link] [DOI:10.1056/NEJMcp1403062]
9. Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36(12):1537-1541. [Link] [DOI:10.1016/j.vaccine.2018.02.029]
10. Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccine Immunother. 2017;13(8):1861-1872. [Link] [DOI:10.1080/21645515.2017.1324373]
11. Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infectious Dis. 2020;7(1):ofaa005. [Link] [DOI:10.1093/ofid/ofaa005]
12. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Osteopat Med. 2009;109(62):13-17. [Link]
13. Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Yamanishi, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1(1):1-18. [Link] [DOI:10.1038/nrdp.2015.16]
14. Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin M. J, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004;5(6):344-356. [Link] [DOI:10.1016/j.jpain.2004.06.001]
15. Lang P-O, Aspinall R. Vaccination for quality of life: herpes-zoster vaccines. Aging Clin Exp Res. 2021;33(4):1113-1122. [Link] [DOI:10.1007/s40520-019-01374-5]
16. Volpi A. Severe complications of herpes zoster. Herpes. 2007;14(2):35-39. [Link]
17. DeWane ME, Smith JS, DeSimone MS, Mostaghimi A. A case of refractory verrucous varicella zoster virus in a patient with persistent pancytopenia after CAR-T therapy. Br J Dermatol. 2022;187(3):e77. [Link] [DOI:10.1111/bjd.21609]
18. Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84:251. [Link] [DOI:10.4103/ijdvl.IJDVL_1021_16]
19. Wolfson LJ, Daniels VJ, Altland A, Black W, Huang W, Ou W. The impact of varicella vaccination on the incidence of varicella and Herpes Zoster in the United States: Updated evidence from observational databases, 1991-2016. Clin Infect Dis. 2020;70(6):995-1002. [Link] [DOI:10.1093/cid/ciz305]
20. Pickering G, Gavazzi G, Gaillat J, Paccalin M, Bloch K, Bouhassira D. Is herpes zoster an additional complication in old age alongside comorbidity and multiple medications? Results of the post hoc analysis of the 12-month longitudinal prospective observational ARIZONA cohort study. BMJ Open. 2016;6(2):e009689. [Link] [DOI:10.1136/bmjopen-2015-009689]
21. Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74(8):1231-8. [Link] [DOI:10.1093/gerona/gly150]
22. Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. Semin Immunol. 2018;40:83-94. [Link] [DOI:10.1016/j.smim.2018.10.010]
23. WHO. Herpes simplex virus [Internet]. Geneva: World Health Organization [cited 2024, May, 20]. Available from: https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus. [Link]
24. Weinberg JM. Herpes zoster: Epidemiology, natural history, and common complications. J Am Acad Dermatol. 2007;57(6):S130-5. [Link] [DOI:10.1016/j.jaad.2007.08.046]
25. Hesham R, Cheong JY, Hasni JM. Knowledge, attitude and vaccination status of varicella among students of Universiti Kebangsaan Malaysia (UKM). Med J Malaysia. 2009;64(3):257-62. [Link]
26. Al Shanbari N, Aldajani A, Almowallad F, Sodagar W, Almaghrabi H, Almuntashiri NS, et al. Assessment of the level of knowledge and attitude towards herpes zoster and its vaccination among individuals at risk in Saudi Arabia. Cureus. 2024:16(2). [Link] [DOI:10.7759/cureus.53572]
27. Yang TU, Cheong HJ, Song JY, Noh JY, Kim WJ. Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South Korea. Hum Vaccin Immunother. 2015;11:719-26. [Link] [DOI:10.1080/21645515.2015.1008885]
28. Lam AC, Chan MY, Chou HY, Ho SY, Li HL, Lo CY, et al. A cross-sectional study of the knowledge, attitude, and practice of patients aged 50 years or above towards herpes zoster in an out-patient setting. Hong Kong Med J. 2017;23(4):365. [Link]
29. Tomas N, Kampanza F. Awareness of varicella-zoster virus among undergraduate students at the University of Namibia. J Public Health Afr. 2022;13(2):1923. [Link] [DOI:10.4081/jphia.2022.1923]
30. Arif N, Qadir MI. Survey about the awareness of chicken pox among biology students. J Hum Virol Retrovirol. 2019;7(1):7-8. [Link] [DOI:10.15406/jhvrv.2019.07.00205]